# ICVAX as a HIV Therapeutic DNA Vaccine

> **NCT06253533** · PHASE1 · COMPLETED · sponsor: **Immuno Cure Holding (HK) Limited** · enrollment: 45 (actual)

## Conditions studied

- Human Immunodeficiency Virus
- Human Immunodeficiency Virus I Infection

## Interventions

- **BIOLOGICAL:** ICVAX
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06253533
- **Lead sponsor:** Immuno Cure Holding (HK) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-14
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-08-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06253533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06253533, "ICVAX as a HIV Therapeutic DNA Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06253533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*